Full-Time

Scientific Director

CMC Team Leader

Updated on 8/13/2026

Deadline 8/31/26
Bristol Myers Squibb

Bristol Myers Squibb

10,001+ employees

Global biopharma researching, developing, delivering medicines

Compensation Overview

$234.1k - $283.7k/yr

+ Incentive cash + Stock opportunities

Company Historically Provides H1B Sponsorship

New Brunswick, NJ, USA

Remote

The role follows BMS’s site-by-design/site-essential occupancy model; on-site presence may be required, with at least 50% on-site for site-by-design roles.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
Supply Chain Management

Get referred to Bristol Myers Squibb

See people who can refer or advise you

Requirements
  • An advanced degree in a relevant scientific discipline.
  • At least 15 years of relevant Chemistry, Manufacturing, and Controls experience in the pharmaceutical industry for the Senior Director level, or at least 12 years for the Director level.
  • A robust or solid understanding of how Chemistry, Manufacturing, and Controls integrates with and partners with non-clinical and clinical development, quality, regulatory, commercial, and other functional areas in pharmaceutical development.
  • The ability to think critically and develop strategic plans aligned with long-term business objectives and innovation.
  • Strong verbal and written communication, problem-solving, and decision-making skills, with the ability to influence and align stakeholders across organizational levels and functions.
  • A proven track record of influencing and building strong partnerships with internal and external stakeholders to achieve strategic goals.
  • An understanding of investment value and the ability to apply risk-balanced and differential investment principles to enhance Chemistry, Manufacturing, and Controls operations and organizational success.
  • The ability to lead, inspire, and develop high-performing teams while fostering a collaborative and inclusive team culture.
  • The ability to manage ambiguity and make decisions with limited information.
  • The ability to operate as an enterprise leader and drive clarity and influence to advance business objectives.
  • Broad and deep understanding of chemical and/or biological, formulation, and analytical development, with a record of leading Chemistry, Manufacturing, and Controls teams through development and commercialization.
  • Experience working with external manufacturing organizations and managing complex supply chains and budgets.
  • Demonstrated success in developing or applying innovative solutions to complex Chemistry, Manufacturing, and Controls technical challenges.
  • Strong knowledge of global regulatory guidelines and requirements, including Food and Drug Administration, European Medicines Agency, and International Council for Harmonisation guidelines.
  • Relevant strategic and tactical project leadership experience and the ability to lead empowered, highly collaborative matrix teams.
Responsibilities
  • Develop and lead comprehensive, compound-specific Chemistry, Manufacturing, and Controls strategies to meet global research and development project needs.
  • Lead interdisciplinary matrix teams that develop and execute integrated Chemistry, Manufacturing, and Controls strategies covering drug substance, drug product, analytical, quality, regulatory, and clinical supplies.
  • Represent Global Product Development and Supply on key research and development project teams and collaborate across clinical, commercial, regulatory, clinical pharmacology, toxicology, and other functional areas.
  • Partner with Product Development and other stakeholders to define and execute project Chemistry, Manufacturing, and Controls strategies, and identify and escalate key issues, risks, and resource-allocation needs.
  • Manage multiple assets across large and small molecules through candidate nomination, first-in-human studies, pivotal clinical studies, and marketing application approvals, including biologics license applications and new drug applications, in partnership with the Chemistry, Manufacturing, and Controls Team Project Manager.
  • Manage the Chemistry, Manufacturing, and Controls project budget and evaluate portfolio trends and the impact of strategic inflection points on project trajectories.
  • Define project opportunities using a return-on-investment approach to optimize Product Development impact within the broader portfolio.
  • Influence Chemistry, Manufacturing, and Controls regulatory strategies and critically review regulatory submissions, briefing booklets, and information requests.
  • Drive operational excellence through best-practice adoption and strategic improvement initiatives, including advanced digital capabilities, planning tools, and program simulation.
  • Partner with the Global Product Development and Supply Business Development group on due-diligence evaluations and activities to bring assets into the Global Product Development and Supply network.
  • Partner with alliance management as needed.
Desired Qualifications
  • Experience in multiple modalities, such as biologics, small molecules, and antibody-drug conjugates.

Bristol Myers Squibb develops and sells medicines for serious diseases, focusing on cancer, immune system disorders, and cardiovascular conditions. Its work starts with research and development to create new therapies, which are then approved by regulators before being used by doctors and patients; the company also offers generic versions and supports biosimilars to expand access. BMS differentiates itself with a broad portfolio of innovative medicines alongside affordable options and a strong emphasis on ESG and regulatory engagement. The goal is to improve patient health by delivering effective, affordable medicines and advancing sustainable healthcare globally.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1887

Get referred to Bristol Myers Squibb

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 revenue hit $12.97 billion, and guidance rose to $49 billion-$50 billion.
  • Growth portfolio reached nearly 60% of revenue, led by Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi.
  • Houston expansion should add 500 jobs and bolster supply reliability before 2030 launches.

What critics are saying

  • Eliquis loses U.S. exclusivity April 1, 2028, triggering immediate multi-source generic erosion.
  • Opdivo faces 2028 patent loss, exposing BMS to biosimilar competition in oncology.
  • Centene's 2026 antitrust suit over Revlimid settlements threatens damages, scrutiny, and reputational damage.

What makes Bristol Myers Squibb unique

  • Opdivo, Eliquis, and Reblozyl still anchor BMS's diversified revenue engine in 2026.
  • Houston's $2.3 billion campus deepens U.S. manufacturing control across small molecules, biologics, and ADCs.
  • BMS pairs drug development with Nvidia supercomputing and Schrödinger Bunsen for faster discovery cycles.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Hybrid Work Options

Professional Development Budget

Growth & Insights and Company News

Headcount

6 month growth

7%

1 year growth

7%

2 year growth

7%
CultureMap Houston
Aug 11th, 2026
Pharmacy giant Bristol Myers Squibb to build $2.3B Houston factory.

Pharmacy giant Bristol Myers Squibb to build $2.3B Houston factory. Aug 11, 2026 | 9:00 am New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site. The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park. BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030. "We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release. The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration." "Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region's ability to support a world-class, digitally advanced supply operation," Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. "This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands." Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program. "Texas is a global hub for life sciences, where today's innovations shape the future of healthcare," Abbott said in a news release. "This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers." "Bristol Myers Squibb's announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing," added Greater Houston Partnership President and CEO Steve Kean. Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here. This story was first published on its sister site InnovationMap. all about that base Houston hero JJ Watt sparks new investment in Texas energy startup. Aug 7, 2026 | 10:45 am Houston Texans legend J.J. Watt is an investor in and customer of Austin-based energy startup Base Power. Courtesy of Base Power Since retiring from the NFL three years ago, Houston Texans legend J.J. Watt has been exploring a new field - investing. In 2023, the former defensive end and current CBS Sports football analyst bought a stake in English soccer team Burnley FC. A year later, he invested in the PopUp Bagels chain. This summer, Watt made what may be his highest-profile investment yet. He contributed to a $1 billion Series D round for Austin-based energy startup Base Power, which has an office in Houston. It's Watts' first investment in the energy sector. "I like companies that solve real problems, and Base is lowering power bills, protecting families, and building the whole thing themselves right here in Texas," Watt said in a company news release. "What impressed me wasn't just how fast they've grown," he adds. "It's that they've already saved Texans millions on their power bills and kept thousands of homes running when the lights went out. That's why I invested." Base Power is building a distributed network of residential batteries that's designed to strengthen the grid and lower electrical bills. The startup now powers more than 30,000 homes in Texas, including the Houston area, and recently expanded to Illinois. Base Power's $1 billion round lifted its valuation to $13 billion. Since being founded in 2023, the startup has raised more than $2.5 billion. "JJ is a legend in this state, and he earned that as much for how he shows up off the field as for what he did on it," says Zach Dell, co-founder and CEO of Base Power. "He spent a full day with us asking every hard question he could think of, and then he switched to Base himself. We're glad to have him partnering with us." Zach Dell is the only son of Austin billionaire Michael Dell, chairman and CEO of Round Rock-based Dell Technologies. Michael Dell grew up in Bellaire. This story was first published on its sister site EnergyCapitalHTX.

Yahoo Finance
Aug 10th, 2026
Bristol Myers Squibb to build $2.3B Houston drug manufacturing campus

Bristol Myers Squibb will build a $2.3 billion drug manufacturing campus in Houston, Texas, as part of its $40 billion US investment commitment over five years. The 600,000-square-foot facility at Generation Park will produce small molecules, biologics, and antibody-drug conjugates. The campus will employ nearly 500 people in operations, production, engineering, quality control, and administration. Construction is expected to support roughly 2,000 workers through 2030 before operations fully launch. Texas Governor Greg Abbott announced Bristol Myers is eligible for a $4.89 million grant through the Texas Enterprise Fund. The company selected Houston after evaluating multiple markets, citing workforce availability in life sciences, incentives, and infrastructure proximity. Bristol Myers raised its full-year revenue forecast to approximately $49 billion to $50 billion earlier this year.

Texas Border Business
Aug 10th, 2026
Bristol Myers Squibb expands in Houston with $2.3 billion facility and 500 new jobs.

Bristol Myers Squibb expands in Houston with $2.3 billion facility and 500 new jobs. Aug 10, 2026 Listen to article (english) Audio Player Translate text to Spanish or other 102 languages! Jul 7, 2026 Jun 26, 2026 Jun 12, 2026 - Advertisement - Texas Border Business - Advertisement - AUSTIN - Governor Greg Abbott announced Bristol Myers Squibb (NYSE: BMY) will establish a new pharmaceutical manufacturing campus in Houston, with a capital investment of approximately $2.3 billion that will create nearly 500 new jobs. A Texas Enterprise Fund (TEF) grant of $4.89 million has been extended to Bristol Myers Squibb. The expansion is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program. "Texas is a global hub for life sciences, where today's innovations shape the future of healthcare," said Governor Abbott. "This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers." Bristol Myers Squibb is a New Jersey-based global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines that help patients prevail over serious diseases. - Advertisement - "This investment reflects our confidence in America's continued leadership in biopharmaceutical innovation," said Bristol Myers Squibb Board Chair and CEO Christopher Boerner, Ph.D. "As part of our $40 billion commitment to the United States, we're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life." "We proudly welcome Bristol Myers Squibb, another leading global pharmaceutical company, to Generation Park," said Generation Park Management District Executive Director Jennifer Mott. "This highly competitive process validates the role our site plays as a vital life science asset both in Texas and nationally. Our commitment to critical investments in infrastructure and a curated ecosystem continues to attract high-value industry clusters that drive long-term prosperity for the region." "Sheldon Independent School District is excited about the opportunities Bristol Myers Squibb will create for student success and future career pathways," said Sheldon ISD Superintendent Dr. Demetrius McCall. "Investments like this help connect classroom learning to real-world opportunities, preparing our students to thrive in a rapidly growing and innovative economy. We believe the impact of this project will open doors for generations of students and families for many years to come." "Bristol Myers Squibb's announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing," said Greater Houston Partnership President and CEO Steve Kean. "Supported by world-class talent, infrastructure, and industry expertise, this investment will create hundreds of high-quality jobs and strengthen Houston's standing as a leading hub for life sciences innovation and investment." - Advertisement - TEF is a performance-based grant, administered by the Texas Economic Development & Tourism Office within the Office of the Governor, that may be awarded to a business relocation or expansion project for which one Texas site is in competition with out-of-state locations to create new, good-paying jobs in the community and attract significant new capital investment to the state. Governor Abbott signed House Bill 5 into law following the 88th Regular Legislative Session, creating the JETI program to attract large, capital-intensive economic development projects that bring new capital investment and create new, good-paying Texas jobs while ensuring robust reporting and transparency. - Advertisement - Aug 10, 2026

Yahoo Finance
Aug 7th, 2026
BMS claims pharma's most powerful supercomputer with Nvidia, beating Lilly and Roche

Bristol Myers Squibb announced an expanded partnership with Nvidia to build what it claims will be "the most powerful and energy-efficient single-owned Nvidia infrastructure in life sciences". BMS joins Eli Lilly and Roche in staking supercomputer superlative claims, though companies use different metrics to measure power. According to Nvidia, BMS' planned system will be the most advanced by operations per second, whilst others measure by GPU count or single system capacity. The companies are pursuing greater computing power to train larger models, run more complex experiments, and accelerate drug discovery. BMS has worked with Nvidia for nearly three years. The company previously used AI to overcome a plateau whilst searching for a clinical candidate for a sickle cell programme. Under the expanded deal, BMS will deploy Nvidia's DGX SuperPOD supercomputer, delivering up to ten times greater performance per megawatt than its predecessor.

Yahoo Finance
Aug 5th, 2026
Bristol Myers Squibb deploys Schrödinger's AI co-scientist Bunsen for drug discovery

Schrödinger has announced a strategic collaboration with Bristol Myers Squibb to deploy Bunsen, its agentic AI co-scientist, within BMS's research organisation. The agreement expands upon their existing partnership, enabling BMS scientists to explore more scientific possibilities and accelerate discovery decisions. Under the collaboration, Schrödinger will work with BMS scientists to develop novel functionality within Bunsen alongside its computational technologies and RetroSynth AI-driven synthesis planning platform. Unlike general-purpose agents, Bunsen is optimised to execute Schrödinger's physics-based computational platform by planning and running complex molecular discovery workflows. The deployment allows BMS to scale its predict-first computational approach across a broader group of scientists, helping them navigate molecular design space more efficiently in discovering innovative medicines.